1. Home
  2. NRDS vs SGMT Comparison

NRDS vs SGMT Comparison

Compare NRDS & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NerdWallet Inc.

NRDS

NerdWallet Inc.

N/A

Current Price

$7.50

Market Cap

640.8M

Sector

Technology

ML Signal

N/A

Logo Sagimet Biosciences Inc. Series A

SGMT

Sagimet Biosciences Inc. Series A

N/A

Current Price

$10.20

Market Cap

761.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
NRDS
SGMT
Founded
2009
2006
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
640.8M
761.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
NRDS
SGMT
Price
$7.50
$10.20
Analyst Decision
Hold
Buy
Analyst Count
5
12
Target Price
$10.13
★ $27.91
AVG Volume (30 Days)
967.8K
★ 1.1M
Earning Date
11-05-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 68.42
N/A
EPS
★ 0.59
N/A
Revenue
★ $836,600,000.00
$2,000,000.00
Revenue This Year
$4.52
N/A
Revenue Next Year
$5.58
N/A
P/E Ratio
$12.38
★ N/A
Revenue Growth
★ 21.67
N/A
52 Week Low
$7.26
$4.50
52 Week High
$16.24
$11.45

Technical Indicators

Market Signals
Indicator
NRDS
SGMT
Relative Strength Index (RSI) 33.41 52.15
Support Level N/A $9.95
Resistance Level $10.16 $11.23
Average True Range (ATR) 0.57 0.71
MACD -0.45 0.10
Stochastic Oscillator 5.72 51.24

Price Performance

Historical Comparison
NRDS
SGMT

About NRDS NerdWallet Inc.

Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. The Company's platform comprises three primary components: Editorial and Content Publishing, Marketplace and Referral Services, and Financial Services. It operates in the United States, Canada, and the United Kingdom.

About SGMT Sagimet Biosciences Inc. Series A

Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.

Share on Social Networks: